Who makes Cilostazol 100 MG?

Cilostazol 100 MG is developed by Kafrelsheikh University.

What development phase is Cilostazol 100 MG in?

Cilostazol 100 MG is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Cilostazol 100 MG

Kafrelsheikh University · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Cilostazol 100 MG
Also known as	group B, Pletaal®, Treatment R, group A
Sponsor	Kafrelsheikh University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
The Effect of Cilostazol on Rheumatoid Arthritis Patients (PHASE2, PHASE3)
Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage (PHASE3)
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (PHASE1, PHASE2)
CiLostAzol for pReventIon of Recurrent sTroke in Africa (PHASE3)
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
Cilostazol for Prevention of Recurrent Stroke Trial (PHASE3)
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cilostazol 100 MG CI brief — competitive landscape report
Cilostazol 100 MG updates RSS · CI watch RSS
Kafrelsheikh University portfolio CI